Swiss National Bank Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Swiss National Bank increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 23.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 432,624 shares of the biopharmaceutical company’s stock after acquiring an additional 82,000 shares during the quarter. Swiss National Bank owned about 0.38% of Alnylam Pharmaceuticals worth $47,091,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. BlackRock Inc. lifted its stake in Alnylam Pharmaceuticals by 6.7% in the first quarter. BlackRock Inc. now owns 8,572,853 shares of the biopharmaceutical company’s stock worth $933,156,000 after acquiring an additional 539,597 shares during the period. Baillie Gifford & Co. lifted its position in Alnylam Pharmaceuticals by 2.7% during the first quarter. Baillie Gifford & Co. now owns 8,411,769 shares of the biopharmaceutical company’s stock valued at $915,621,000 after buying an additional 225,046 shares during the period. Geode Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 1,239,487 shares of the biopharmaceutical company’s stock valued at $142,622,000 after buying an additional 50,788 shares during the period. Norges Bank purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $115,540,000. Finally, First Trust Advisors LP lifted its position in Alnylam Pharmaceuticals by 41.6% during the first quarter. First Trust Advisors LP now owns 847,234 shares of the biopharmaceutical company’s stock valued at $92,221,000 after buying an additional 249,019 shares during the period. 92.81% of the stock is owned by institutional investors.

ALNY has been the subject of several recent research reports. BidaskClub lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 30th. Royal Bank of Canada initiated coverage on Alnylam Pharmaceuticals in a research report on Tuesday, May 12th. They set a “sector perform” rating and a $150.00 price objective for the company. Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $148.00 to $162.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, February 7th. Finally, Barclays raised their price objective on Alnylam Pharmaceuticals from $143.00 to $156.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $143.75.

In related news, EVP Laurie Keating sold 10,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $139.00, for a total value of $1,390,000.00. Following the completion of the sale, the executive vice president now directly owns 24,492 shares in the company, valued at approximately $3,404,388. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John Maraganore sold 34,765 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $143.22, for a total value of $4,979,043.30. Following the completion of the sale, the chief executive officer now owns 232,354 shares of the company’s stock, valued at $33,277,739.88. The disclosure for this sale can be found here. Insiders sold a total of 96,812 shares of company stock valued at $13,878,051 over the last quarter. 3.50% of the stock is owned by corporate insiders.

NASDAQ ALNY opened at $140.52 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $65.89 and a one year high of $151.84. The stock has a 50-day moving average of $131.05 and a 200 day moving average of $117.87. The company has a current ratio of 4.68, a quick ratio of 4.48 and a debt-to-equity ratio of 0.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.62) EPS for the quarter, topping the consensus estimate of ($1.89) by $0.27. Alnylam Pharmaceuticals had a negative return on equity of 57.63% and a negative net margin of 310.01%. The company had revenue of $71.94 million during the quarter, compared to the consensus estimate of $90.45 million. During the same period last year, the company earned ($1.42) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 173.6% on a year-over-year basis. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.2 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Further Reading: How To Calculate Debt-to-Equity Ratio

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.